(Albany, USA) DelveInsight’s “Aortic Stenosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Aortic Stenosis, historical and forecasted epidemiology as well as the Aortic Stenosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Aortic Stenosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Aortic Stenosis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Aortic Stenosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Aortic Stenosis market.
Request for a Free Sample Report @ Aortic Stenosis Market Forecast
Some facts of the Aortic Stenosis Market Report are:
- According to DelveInsight, Aortic Stenosis market size is expected to grow at a decent CAGR by 2032.
- Leading Aortic Stenosis companies working in the market are Boston Scientific Corporation, Medtronic plc, Novartis, Boston Scientific Corporation, Abbott Laboratories, LivaNova PLC, Edwards Lifesciences Corporation, Anteris Technologies Ltd., Peijia Medical Technology (Suzhou) Co., Ltd., CryoLife, JenaValve Technology, Shanghai MicroPort CardioFlow Medtech Co., Thubrikar Aortic Valve, LifeNet Health, Coroneo, Meril Life Sciences Pvt. Ltd., AstraZeneca plc, Anteris Technologies Ltd. and others.
- Key Aortic Stenosis Therapies expected to launch in the market are Pelacarsen (TQJ230) 80mg, SAPIEN 3 / SAPIEN 3 Ultra, TaurusOne® transcatheter aortic valve replacement system, VitaFlow™ II Transcatheter Aortic Valve System, DurAVRTM THV System, ACURATE neo2™ Transfemoral TAVR System, DurAVRTM THV System, CoreValve TAVR System, MDT-2215 aortic valve bioprosthesis, transShield Embolic Protection System, Enavogliflozin, and others.
- In June 2023, Edwards Lifesciences announced a study to establish the safety and effectiveness of the Edwards SAPIEN 3/ SAPIEN 3 Ultra Transcatheter Heart Valve in subjects with moderate, calcific aortic stenosis.
- In May 2023, Anteris Technologies Ltd announced a study to evaluate the safety and feasibility of DurAVR™ THV System in the treatment of subjects with symptomatic severe native aortic stenosis.
- In April 2023, Novartis announced a study to evaluate the efficacy and safety of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.
Aortic Stenosis Overview
Aortic stenosis is a cardiovascular condition characterized by the narrowing or obstruction of the aortic valve, which is responsible for regulating blood flow from the heart’s left ventricle to the aorta and the rest of the body. The narrowing of the valve restricts the blood flow, leading to various symptoms and complications. Aortic stenosis is commonly caused by age-related calcification of the valve, congenital abnormalities, or other underlying conditions. Symptoms may include chest pain, shortness of breath, fatigue, dizziness, and fainting. Severe cases may require surgical intervention, such as aortic valve replacement, to restore proper blood flow. Regular monitoring and management are crucial for individuals with aortic stenosis.
Learn more about Aortic Stenosis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/aortic-stenosis-market
Aortic Stenosis Market
The Aortic Stenosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Aortic Stenosis market trends by analyzing the impact of current Aortic Stenosis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Aortic Stenosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Aortic Stenosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Aortic Stenosis market in 7MM is expected to witness a major change in the study period 2019-2032.
Aortic Stenosis Epidemiology
The Aortic Stenosis epidemiology section provides insights into the historical and current Aortic Stenosis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Aortic Stenosis market report also provides the diagnosed patient pool, trends, and assumptions.
- As per a study by Pujari et al. (2021), the prevalence of calcific aortic stenosis is about 1% to 2% in patients aged 65 or more, 12% in patients aged 65 or more, and about 3.4% of patients aged greater than 75 have severe aortic stenosis.
- The prevalence of aortic sclerosis ranges from 9-45% in patients with a mean age of 54 to 81 and increases with age.
- According to a journal, the prevalence in Japan of any valve disease is 2.5%. Of those with valve disease, about 0.4% have aortic stenosis.
- According to Grave et al. (2020), in 2017, the guidelines of the European Society of Cardiology and the European Association for Cardio‐Thoracic Surgery recommended SAVR or TAVI, depending on symptoms, AS severity, comorbidities, and the clinical evaluation of the heart team.
Explore more about Aortic Stenosis Epidemiology @ https://www.delveinsight.com/sample-request/aortic-stenosis-market
Aortic Stenosis Drugs Uptake
This section focuses on the uptake rate of the potential Aortic Stenosis drugs recently launched in the Aortic Stenosis market or expected to be launched in 2019-2032. The analysis covers the Aortic Stenosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Aortic Stenosis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Aortic Stenosis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Aortic Stenosis Pipeline Development Activities
The Aortic Stenosis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Aortic Stenosis key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Aortic Stenosis pipeline development activities @ https://www.delveinsight.com/sample-request/aortic-stenosis-market
Aortic Stenosis Therapeutics Assessment
Major key companies are working proactively in the Aortic Stenosis Therapeutics market to develop novel therapies which will drive the Aortic Stenosis treatment markets in the upcoming years are Boston Scientific Corporation, Medtronic plc, Novartis, Boston Scientific Corporation, Abbott Laboratories, LivaNova PLC, Edwards Lifesciences Corporation, Anteris Technologies Ltd., Peijia Medical Technology (Suzhou) Co., Ltd., CryoLife, JenaValve Technology, Shanghai MicroPort CardioFlow Medtech Co., Thubrikar Aortic Valve, LifeNet Health, Coroneo, Meril Life Sciences Pvt. Ltd., AstraZeneca plc, Anteris Technologies Ltd. and others.
Learn more about the emerging Aortic Stenosis devices, therapies & key companies @ https://www.delveinsight.com/sample-request/aortic-stenosis-market
Aortic Stenosis Report Key Insights
1. Aortic Stenosis Patient Population
2. Aortic Stenosis Market Size and Trends
3. Key Cross Competition in the Aortic Stenosis Market
4. Aortic Stenosis Market Dynamics (Key Drivers and Barriers)
5. Aortic Stenosis Market Opportunities
6. Aortic Stenosis Therapeutic Approaches
7. Aortic Stenosis Pipeline Analysis
8. Aortic Stenosis Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Aortic Stenosis Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Aortic Stenosis Competitive Intelligence Analysis
4. Aortic Stenosis Market Overview at a Glance
5. Aortic Stenosis Disease Background and Overview
6. Aortic Stenosis Patient Journey
7. Aortic Stenosis Epidemiology and Patient Population
8. Aortic Stenosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Aortic Stenosis Unmet Needs
10. Key Endpoints of Aortic Stenosis Treatment
11. Aortic Stenosis Marketed Products
12. Aortic Stenosis Emerging Therapies
13. Aortic Stenosis Seven Major Market Analysis
14. Attribute Analysis
15. Aortic Stenosis Market Outlook (7 major markets)
16. Aortic Stenosis Access and Reimbursement Overview
17. KOL Views on the Aortic Stenosis Market
18. Aortic Stenosis Market Drivers
19. Aortic Stenosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting